Plasma. Proteins
Plasma wall studies, exploring plasma-wall interaction scenarios with Li coating and Li-liquid limiter concepts.
Plasma wall interaction and divertor physics;
Plasma. (a) Cerus and BHC acknowledge and agree that the Cooperative Development Work, as defined in the RBC/FFP Agreement, for the Plasma System;
(i) continues with respect to activities directed toward obtaining CE Xxxx in the European Territory;
(ii) is terminated, effective January 1, 2005, with respect to activities directed to North America;
(b) With respect to activities directed toward obtaining CE Xxxx for the Plasma System and related manufacturing and validation, Xxxxxx agrees, at Cerus’ request and expense, to carry out the further development activities set forth on Exhibit C to this Agreement within the time schedules set forth on such Exhibit for such activities. The charge for such activities will not exceed the amount set forth on such Exhibit, provided that the scope of such activities is not expanded. Cerus agrees to fund those Xxxxxx activities, as well as Cerus activities, directed toward completing the application for CE Xxxx, including through funding from the Escrow Account pursuant to Section 2.8, above.
(c) With respect to the countries of the BioOne Territory, it is acknowledged that Cerus has been discussing with BioOne and Xxxxxx a potential transaction related to the Plasma System that is similar to the transaction previously entered into for the Platelet System. In the event such a transaction is entered into, it is anticipated that development and commercialization will be carried on by BioOne. Pending the completion of the transactions, the Parties do not expect that any Cooperative Development work will be funded specifically directed to the countries of the BioOne Territory. The parties agree to cooperate to supply information to BioOne and engage in discussions with BioOne to facilitate the completion of such transaction. Such activities will not be considered Cooperative Development work that is subject to funding under the RBC/FFP Agreement. In the event that such transaction is not entered into with BioOne or another entity within [*] months of the date of this Agreement, the Cooperative Development Work for the Plasma System will be considered terminated with respect to the countries of the BioOne Territory. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
(d) With respect to activities concerning the Plasma System directed to the ...
Plasma. Pull Through Welder (Sub Arc) 4. Cladding Line 5. Purlin Line 6. Powder Paint
Plasma. Cortisol has been extensively measured in plasma, urine and has also been measured in CSF. Single and multiple measurements have been used. In plasma and urine, 24-hr collections have been attempted to provide a stable measure of adrenocortical output. Plasma concentrations of single or multiple cortisol levels have also been extensively used. There is a large individual variation with normal morning plasma cortisol values ranging between 165-690 nmol/l (Xxxxxx et al., 1996). Plasma free and salivary cortisol do correlate; however, total plasma cortisol shows a non linear correlation with saliva, as the former depends on the relative saturation of CBG (Xxxxxx-Xxxxxxxx et al., 1998; Xxxxxx et al., 1983). Due to more than 90% of plasma cortisol being protein bound, the results of the conventional assay are affected by drugs, oral contraceptive use or conditions such as pregnancy that alter CBG levels. Few laboratories have developed methods for the measurement of free levels of plasma cortisol. Urinary free cortisol is an integrated measure of plasma free cortisol; as cortisol secretion increases, the binding capacity of CBG is exceeded, resulting in a disproportionate rise in urinary free cortisol. Normal values are less than 220 to 330 nmol/l in 24 hours depending on the assay used. It may not always provide a reliable measurement method of the HPA axis activity as urinary free cortisol represents only 2- 3% of the daily adrenal cortisol secretion. Instead cortisol metabolites are routinely measured. Furthermore some measurement methods have large variability at the lower part of the analytical range (Xxxxxx et al., 2006)
Plasma. In humans, plasma DHEA concentrations are only found in the range of 1−4 ng/ml, but circulating DHEA-S concentrations are much higher on a molar basis, between 250 and 500 times higher in women and men, respectively (Xxxxxxx-Xxxxxx et al., 1986; Xxxxxx et al., 1995). In animals administration of CRH or ACTH leads to significant changes in plasma and brain DHEA levels but no such changes are observed in DHEA-S concentrations. DHEA-S response to exogenous ACTH administration is smaller than that of DHEA (Xxxxxxxx et al., 2005).
Plasma. Artificial Limbs and eyes; Casts; Splints; Braces and Rentalof its administration -Vision Care: effective November during and month period. UnlimitedLenses. Contact lenses if medically required (no sun glasses). HospitalRoom Rate -Coverage outside Canada for Doctorsand Hospitalwithin fee schedule -Hearing Aids (6)
Plasma. To enable the CCPs to independently deploy mixed-precision within their codes in an effective manner, we will develop a general framework for its use and provide training to the CCPs (web-based training and the provision of workshops at CCP meetings). We will also continue our code-coupling effort and will work closely with CCP-WSI to identify bottlenecks and improve the coupling methods used to give better performance on HPC platforms. Collectively, the CCPs provide a large number of software packages to their users and information about these packages is scattered across different websites and in various journals. We will perform an audit of these software packages, gathering information from the CCPs on a number of metrics such as the type of software license, support available, and performance of the code on HPC provisions. Software Outlook Milestone Target Date CCP5’s use of mixed-precision within DL_MESO (CCP5), in which Xxxxxxx Xxxxxx has a specific request to look into splitting a particular DP measurement into two contributions A+B, where A is large (relative to B) and unchanging, and B is continuously modified but should be able to be calculated in SP and stored in SP. Removed. Following further reduced precision experiments in DL_POLY, this was dropped in favour of extending the remit of the training package. The DL_POLY experiments also implied that the DL_MESO proposal was unlikely to yield good enough savings in execution time Q2 2017 Q3 2017 Coupling Type 1: Simplest Case: OpenFOAM-to-OpenFOAM coupling. How is the coupling done in Floating Buoy test example? Does it scale well? What percentage of time is spent doing the coupling. Investigate reason for general OpenFOAM scaling problems for this problem Complete. Xxxxxx Xxxxxx was able to get an extensive amount of data, which is going to form the basis of a joint paper between Xxxxxx and Xx Xxxxxxx Q2 2017 Q3 2017 Work packet revolving around FLAME from CCP-Plasma Removed. Dropped in favour of the expanded mixed precision training package. Q3 2017 Q4 2017 Development of a more general framework to guide the CCPs in deciding whether mixed-precision would be a valuable attribute to their codes. This would involve the production of written training material as well as the possibility of a webinar. Ongoing. In the final stages of producing the training package. Some of the webinars have been recorded. Will move to 2018/19 plans Q4 2017 Investigating the effects of using mixed-precision approache...
Plasma. Processes to conduct kickoff meeting to establish design and construction goals Effective date + one week
